Abstract
The occurrence of an alloantibody directed against von Willebrand factor in a multitransfused patient with severe (type III) von Willebrand disease was first reported in 2 consecutive studies by Sarji et al. (1974) and Stratton et al. (1975). After this, 14 additional cases of alloantibodies were described and reviewed by Mannucci and Mari (1984). A survey carried out on behalf of the World Federation of Hemophilia identified 6 additional cases that, added to the 15 cases previously reported, bring to 21 the total number of patients reported so far with anti-von Willebrand factor alloantibodies (Mannucci and Cattaneo, 1991). In the frame of the survey, Hanna (1989) reported an antibody directed towards factor VIII (F.VIII) in a girl with severe von Willebrand disease. Since this antibody did not apparently react with von Willebrand factor, it will not be reviewed here.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bloom AL, Peake IR, Furlong RA and Davies BL. High potency factor VIII concentrate: more effective than cryoprecipitate in a patient with von Willebrand’s disease and inhibitor. Thromb Res 16: 847 (1979).
Egberg N and Blomback M. On the characterization of acquired inhibitors to ristocetin-induced platelet aggregation found in patients with von Willebrand’s disease. Thromb Res 9: 527 (1976).
Ginsburg D and Sadler JE. von Willebrand disease: a database of point mutations, insertions and deletions. Thromb Haemostas 69: 177 (1993).
Hanna WT. Replacement therapy for surgery in type III von Willebrand patient with inhibitors to factor VIII procoagulant. Thromb Haemostas 62: 224 (1989) (abstract).
Lenk H, Weissbach G and Donula M. Ein Hemmkorper bei von Willebrand Jurgens- Syndrome and seine Wirkung aur die Eigenschaften des Factor VIII molekuls. Folia Haematol 105: 826 (1978).
Lopez-Fernandez MF, Martin R, Lopez-Berges C, Ramos F, de Bosch N and Battle J. Further specific characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. Blood 72: 116 (1988).
Lopez-Fernandez MF, Martin R, Lopez-Berges C, Ramos F, de Bosch N and Battle J. Further specific characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. Blood 72: 116 (1988).
Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N and Lavergne JM. Precipitating antibodies in von Willebrand’s disease. Nature 262: 141 (1976).
Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD and Mowbray JF. Precipitating antibodies to factor VIII-von Willebrand factor in von Willebrand’s disease: effects on replacement therapy. Blood 57: 25 (1981).
Mannucci PM and Mari D. Antibodies to factor VTII/von Willebrand factor in congenital and acquired von Willebrand’s disease. In: LW Hoyer ed. Factor Villi inhibitors. New York: Alan R. Liss, 109 (1984).
Mannucci PM, Bloom A, Larrieu MJ, Nilsson IM and West RR. Atherosclerosis and von Willebrand factor. Prevalence of severe von Willebrand disease in Western Europe and Israel. Br J Haematol 57: 166 (1984).
Mannucci PM, Tamaro G, Nerchi G, Candotti G, Federici A, Altieri D and Tedesco F. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Hematol 39: 467 (1987).
Mannucci PM and Cattaneo M. Alloantibodies in congenital von Willebrand disease. Res Clin Lab 21: 119 (1991).
Maragall S, Castillo R, Ordinas A, Iiendo F and Rodriquez M. Inhibition of Willebrand factor in von Willebrand’s disease. Thromb Res 14: 495 (1979).
Miller CH, Bussel JB and Hilgartner MW. Characteristics of inhibitors in severe von Willebrand’s disease. Thromb Haemost 50: 34 (1983) (abstract).
Ngo K, Glotz VT, Koziol JA, et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand’s disease. Proc Natl Acad Sci USA 85: 2753 (1988).
Peake IR, Lidde CB, Moodie P, et al. Severe type III von Willebrand’s disease caused by deletion of exon 42 of the von Willebrand factor gene: family studies that identify carriers of the condition and a compound heterozygous individual. Blood 72: 6544 (1990).
Ruggeri ZM, Ciavarella N, Mannucci PM, Molinari A, Dammaco F, Lavergne JM and Meyer D. Familial incidence of precipitating antibodies in von Willebrand’s disease: a study of four cases. J Lab. Clin Med 94: 60 (1979).
Sarji KE, Stratton RD, Wagner RH and Brinkhous KM. Nature of von Willebrand factor. A new assay and a specific inhibitor. Proc Natl Acad Sci USA 71: 2937 (1974).
Shelton-Inloes BB, Chebab FF, Mannucci PM, Federici AB and Sadler JE. Gene deletions correlate with the development of antibodies in von Willebrand disease. J Clin Invest 79: 1459 (1987).
Shoa’i I, Lavergne JM, Ardaillou N, Obert B, Ala F and Meyer D. Heterogeneity of von Willebrand’s disease; study of 40 Iranian cases. Br J Haematol 37: 67 (1977).
Stratton RD, Wagner RH, Webster WP and Brinkhous KM. Antibody nature of circulating inhibitor of plasma von Willebrand factor. Proc Natl Acad Sci USA 72: 4167 (1975).
Zhang ZP, Lindstedt M, Falk G, Blomback M, Egberg N and Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and I. Am J Hum Genet 51: 850 (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Mannucci, P.M., Federici, A.B. (1995). Antibodies to von Willebrand factor in von Willebrand disease. In: Aledort, L.M., Hoyer, L.W., Lusher, J.M., Reisner, H.M., White, G.C. (eds) Inhibitors to Coagulation Factors. Advances in Experimental Medicine and Biology, vol 386. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0331-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0331-2_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8001-6
Online ISBN: 978-1-4613-0331-2
eBook Packages: Springer Book Archive